Schulz Marcus 4/A
4/A · BIOLIFE SOLUTIONS INC · Filed May 16, 2023
Insider Transaction Report
Form 4/AAmended
Schulz Marcus
Vice President, Global Sales
Transactions
- Sale
Common Stock
2023-04-06$20.03/sh−771$15,443→ 44,619 total - Exercise/Conversion
Common Stock
2023-03-31+2,912→ 45,390 total - Exercise/Conversion
Restricted Stock Award
2023-03-31−2,912→ 0 totalExercise: $0.00→ Common Stock (2,912 underlying)
Footnotes (3)
- [F1]The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
- [F2]The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.
- [F3]This reflects the total amount beneficially owned by the reporting person as of April 10, 2023. Subsequent Form 4's filed by the reporting person after April 10, 2023 do not currently reflect the vesting of the 2,912 shares.